文献速递主动脉疾病

糖尿病对腹主动脉瘤两年生长速度的影响

The effect of diabetes on abdominal aortic aneurysm growth over 2 years.
PubMed 文献 · J Vasc Surg · 2021-10-23

本研究为N-TA3CT试验的二次分析,纳入250例腹主动脉瘤最大横径3.5-5cm的患者,比较有无糖尿病者的瘤体生长速度。结果显示糖尿病患者中位生长率0.12 cm/y,非糖尿病者0.19 cm/y,校正后糖尿病仍与较慢生长独立相关。

要点

  • 糖尿病患者腹主动脉瘤中位生长率较非糖尿病者降低超过35%。
  • 糖尿病与更严重的血管共病相关,但校正后仍显示生长减慢。
  • 糖尿病患者中快速生长(>0.5 cm/y)少见。

核心结论

  • 糖尿病患者腹主动脉瘤中位生长率较非糖尿病者降低超过35%,且校正后仍显著。
  • 该效应可能延迟达到修复阈值的时间,快速生长在糖尿病患者中不常见。

研究设计与样本

  • N-TA3CT安慰剂对照多中心试验的二次分析,原试验评估多西环素对261例AAA患者的作用。
  • 纳入250例有足够影像的患者,AAA最大横径3.5-5 cm,其中糖尿病56例(22.4%),无糖尿病194例(77.6%)。
  • 主要结局为CT测量的最大横径自基线的变化,次要结局为AAA生长模式。

主要发现

  • 糖尿病组基线最大横径4.32 cm,非糖尿病组4.30 cm,差异无统计学意义。
  • 糖尿病组中位生长率0.12 cm/y(IQR 0.07-0.22),非糖尿病组0.19 cm/y(IQR 0.12-0.27),未校正分析P < .0001。
  • 校正其他相关临床因素后,糖尿病仍与AAA生长显著相关(coef -0.057;P < .0001)。
  • 糖尿病与更高的体重指数、高胆固醇血症和冠心病患病率相关(P < .05)。
  • 糖尿病与更频繁的动脉粥样硬化和高血压治疗相关,包括他汀、ACEI、ARB、抗血小板和利尿剂(P < .05)。

临床怎么用

  • 对于合并糖尿病的腹主动脉瘤患者,可预期其瘤体生长速度较慢,监测间隔可个体化考虑。
  • 糖尿病患者的快速生长少见,但仍需按指南定期影像随访。

局限性

  • 本研究为N-TA3CT试验的二次分析,原试验非专门设计验证糖尿病对AAA生长的影响。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Abdominal aortic aneurysm (AAA) is a common progressive disease and a significant cause of morbidity and mortality. Prior investigations have shown that diabetes mellitus (DM) may be relatively protective of AAA incidence and growth. The Non-invasive Treatment of Aortic Aneurysm Clinical Trial (N-TA3CT) is a contemporary study of small AAA growth that provides a unique opportunity to validate and explore the effect of DM on AAA. Confirming the effect of DM on AAA growth in this study may present opportunities to explore for clues to potential biologic mechanisms as well as inform current patient management. METHODS: This is a secondary analysis examining the association of diabetes and aneurysm growth within N-TA3CT: a placebo-controlled multicenter trial of doxycycline in 261 patients with AAA maximum transverse diameters (MTDs) between 3.5 and 5 cm. The primary outcome is the change in the MTD from baseline as determined by computed tomography (CT) scans obtained during the trial. Secondary outcome is the growth pattern of the AAA. Baseline characteristics and growth patterns were assessed with t tests (continuous) or χ2 tests (categorical). Unadjusted and adjusted longitudinal analyses were performed with a repeated measures linear mixed model to compare AAA growth rates between patients with and without diabetes. RESULTS: Of 261 patients, 250 subjects had sufficient imaging and were included in this study. There were 56 patients (22.4%) with diabetes and 194 (77.6%) without. Diabetes was associated with higher body mass index and increased rates of hypercholesterolemia and coronary artery disease (P < .05). Diabetes was also associated with increased frequency of treatment for atherosclerosis and hypertension including treatment with statin, angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, anti-platelet, and diuretic therapy (P < .05). Baseline MTD was not significantly different between those with (4.32 cm) and without DM (4.30 cm). Median growth rate for patients with diabetes was 0.12 cm/y (interquartile range, 0.07-0.22 cm/y) and 0.19 cm/y (interquartile range, 0.12-0.27 cm/y) in patients without DM, which was significantly different on unadjusted analysis (P < .0001). Diabetes remained significantly associated with AAA growth after adjustment for other relevant clinical factors (coef, -0.057; P < .0001). CONCLUSIONS: Patients with diabetes have more than a 35% reduction in the median growth rates of AAA despite more severe concomitant vascular comorbidities and similar initial sizes of aneurysms. This effect persists and remains robust after adjusted analysis; and slower growth rates may delay the time to reach repair threshold. Rapid growth (>0.5 cm/y) is infrequent in patients with DM.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Nordness MJ, Baxter BT, Matsumura J, et al. The effect of diabetes on abdominal aortic aneurysm growth over 2 years. J Vasc Surg. 2021. PMID: 34695550. doi:10.1016/j.jvs.2021.10.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。